(UHS) Universal Health - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 11.242m USD | Total Return: -2.7% in 12m

Stock Hospitals, Behavioral Health, Insurance, Management
Total Rating 49
Risk 91
Buy Signal -0.76
Medical Care Facilities -7.5
Health Care Facilities -12.2
Market Cap: 11,242m
Avg Trading Vol: 150M USD
ATR: 3.45%
Peers RS (IBD): 28.9
Risk 5d forecast
Volatility32.8%
Rel. Tail Risk-12.5%
Reward TTM
Sharpe Ratio-0.01
Alpha-13.74
Character TTM
Beta0.885
Beta Downside0.487
Drawdowns 3y
Max DD35.64%
CAGR/Max DD0.37
EPS (Earnings per Share) EPS (Earnings per Share) of UHS over the last years for every Quarter: "2021-03": 2.44, "2021-06": 3.76, "2021-09": 2.67, "2021-12": 2.95, "2022-03": 2.15, "2022-06": 2.2, "2022-09": 2.54, "2022-12": 3.02, "2023-03": 2.34, "2023-06": 2.53, "2023-09": 2.55, "2023-12": 3.13, "2024-03": 3.7, "2024-06": 4.31, "2024-09": 3.71, "2024-12": 4.92, "2025-03": 4.84, "2025-06": 5.35, "2025-09": 5.69, "2025-12": 5.88,
EPS CAGR: 30.77%
EPS Trend: 95.1%
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of UHS over the last years for every Quarter: 2021-03: 3012.987, 2021-06: 3197.88, 2021-09: 3155.999, 2021-12: 3275.251, 2022-03: 3292.956, 2022-06: 3323.407, 2022-09: 3336.027, 2022-12: 3446.98, 2023-03: 3467.518, 2023-06: 3548.138, 2023-09: 3562.774, 2023-12: 3703.546, 2024-03: 3843.582, 2024-06: 3907.604, 2024-09: 3963.027, 2024-12: 4113.722, 2025-03: 4099.72, 2025-06: 4283.816, 2025-09: 4495.245, 2025-12: 4486.048,
Rev. CAGR: 8.59%
Rev. Trend: 99.0%
Last SUE: -0.34
Qual. Beats: 0
Description: UHS Universal Health March 04, 2026

Universal Health Services, Inc. (UHS) operates acute care hospitals and behavioral health facilities across the United States. The companys business model is diversified, encompassing both inpatient and outpatient services.

UHSs operations are divided into two primary segments: Acute Care Hospital Services and Behavioral Health Care Services. Acute care facilities typically provide short-term treatment for severe illnesses or injuries. Behavioral health services address mental health and substance abuse conditions, a growing area within the healthcare sector.

The company provides a comprehensive range of medical services including surgery, internal medicine, obstetrics, emergency care, and oncology. Additionally, UHS offers support services such as commercial health insurance, capital resources, and various management functions to its facilities. To gain further insights into UHSs operational performance and financial health, consider exploring detailed analyses on ValueRay.

Headlines to Watch Out For
  • Behavioral health services demand drives revenue growth
  • Acute care hospital admissions impact financial performance
  • Staffing shortages and labor costs compress margins
  • Government healthcare policies influence reimbursement rates
  • Commercial insurance contracts affect profitability
Piotroski VR‑10 (Strict, 0-10) 8.0
Net Income: 1.49b TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.56 > 1.0
NWC/Revenue: 0.97% < 20% (prev 3.83%; Δ -2.86% < -1%)
CFO/TA 0.12 > 3% & CFO 1.86b > Net Income 1.49b
Net Debt (5.37b) to EBITDA (2.74b): 1.96 < 3
Current Ratio: 1.05 > 1.5 & < 3
Outstanding Shares: last quarter (64.5m) vs 12m ago -3.89% < -2%
Gross Margin: 90.45% > 18% (prev 0.90%; Δ 8.95k% > 0.5%)
Asset Turnover: 114.1% > 50% (prev 109.4%; Δ 4.76% > 0%)
Interest Coverage Ratio: 13.63 > 6 (EBITDA TTM 2.74b / Interest Expense TTM 155.8m)
Altman Z'' 3.53
A: 0.01 (Total Current Assets 3.41b - Total Current Liabilities 3.24b) / Total Assets 15.96b
B: 0.50 (Retained Earnings 7.99b / Total Assets 15.96b)
C: 0.14 (EBIT TTM 2.12b / Avg Total Assets 15.21b)
D: 0.85 (Book Value of Equity 7.28b / Total Liabilities 8.55b)
Altman-Z'' Score: 3.53 = A
Beneish M -2.91
DSRI: 1.09 (Receivables 2.60b/2.18b, Revenue 17.36b/15.83b)
GMI: 0.99 (GM 90.45% / 89.97%)
AQI: 1.00 (AQ_t 0.32 / AQ_t-1 0.32)
SGI: 1.10 (Revenue 17.36b / 15.83b)
TATA: -0.02 (NI 1.49b - CFO 1.86b) / TA 15.96b)
Beneish M-Score: -2.91 (Cap -4..+1) = A
What is the price of UHS shares? As of March 31, 2026, the stock is trading at USD 182.10 with a total of 513,095 shares traded.
Over the past week, the price has changed by -3.18%, over one month by -11.56%, over three months by -19.01% and over the past year by -2.70%.
Is UHS a buy, sell or hold? Universal Health has received a consensus analysts rating of 3.79. Therefor, it is recommend to hold UHS.
  • StrongBuy: 7
  • Buy: 1
  • Hold: 11
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the UHS price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 248.8 36.6%
Analysts Target Price 248.8 36.6%
UHS Fundamental Data Overview March 29, 2026
P/E Trailing = 7.9671
P/E Forward = 7.837
P/S = 0.6474
P/B = 1.5601
P/EG = 1.2848
Revenue TTM = 17.36b USD
EBIT TTM = 2.12b USD
EBITDA TTM = 2.74b USD
Long Term Debt = 4.00b USD (from longTermDebt, last quarter)
Short Term Debt = 821.4m USD (from shortTermDebt, last quarter)
Debt = 5.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.37b USD (from netDebt column, last quarter)
Enterprise Value = 16.61b USD (11.24b + Debt 5.51b - CCE 137.8m)
Interest Coverage Ratio = 13.63 (Ebit TTM 2.12b / Interest Expense TTM 155.8m)
EV/FCF = 20.00x (Enterprise Value 16.61b / FCF TTM 830.6m)
FCF Yield = 5.00% (FCF TTM 830.6m / Enterprise Value 16.61b)
FCF Margin = 4.78% (FCF TTM 830.6m / Revenue TTM 17.36b)
Net Margin = 8.57% (Net Income TTM 1.49b / Revenue TTM 17.36b)
Gross Margin = 90.45% ((Revenue TTM 17.36b - Cost of Revenue TTM 1.66b) / Revenue TTM)
Gross Margin QoQ = 90.58% (prev 90.78%)
Tobins Q-Ratio = 1.04 (Enterprise Value 16.61b / Total Assets 15.96b)
Interest Expense / Debt = 0.77% (Interest Expense 42.5m / Debt 5.51b)
Taxrate = 22.98% (133.6m / 581.4m)
NOPAT = 1.64b (EBIT 2.12b * (1 - 22.98%))
Current Ratio = 1.05 (Total Current Assets 3.41b / Total Current Liabilities 3.24b)
Debt / Equity = 0.76 (Debt 5.51b / totalStockholderEquity, last quarter 7.28b)
Debt / EBITDA = 1.96 (Net Debt 5.37b / EBITDA 2.74b)
Debt / FCF = 6.46 (Net Debt 5.37b / FCF TTM 830.6m)
Total Stockholder Equity = 7.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.79% (Net Income 1.49b / Total Assets 15.96b)
RoE = 21.03% (Net Income TTM 1.49b / Total Stockholder Equity 7.08b)
RoCE = 19.16% (EBIT 2.12b / Capital Employed (Equity 7.08b + L.T.Debt 4.00b))
RoIC = 13.94% (NOPAT 1.64b / Invested Capital 11.73b)
WACC = 6.30% (E(11.24b)/V(16.75b) * Re(9.10%) + D(5.51b)/V(16.75b) * Rd(0.77%) * (1-Tc(0.23)))
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.03%
[DCF] Terminal Value 87.36% ; FCFF base≈947.7m ; Y1≈1.17b ; Y5≈1.99b
[DCF] Fair Price = 874.4 (EV 52.45b - Net Debt 5.37b = Equity 47.08b / Shares 53.8m; r=6.30% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 95.13 | EPS CAGR: 30.77% | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.04 | Revenue CAGR: 8.59% | SUE: -0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.89 | Chg7d=-0.003 | Chg30d=+0.086 | Revisions Net=-1 | Analysts=12
EPS current Year (2026-12-31): EPS=23.46 | Chg7d=+0.010 | Chg30d=+0.071 | Revisions Net=-1 | Growth EPS=+7.9% | Growth Revenue=+6.4%
EPS next Year (2027-12-31): EPS=25.58 | Chg7d=+0.007 | Chg30d=-0.539 | Revisions Net=-1 | Growth EPS=+9.0% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: -0.11 (4 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -3.5% (Discount Rate 9.1% - Earnings Yield 12.6%)
[Growth] Growth Spread = +10.2% (Analyst 6.8% - Implied -3.5%)
Additional Sources for UHS Stock Fund Manager Positions: Dataroma · Stockcircle